FEMY
Femasys Inc.
There isn't enough reported data to score FEMY yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
FEMY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
FEMY's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
FEMY PE Valuation
FEMY has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
FEMY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect FEMY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
FEMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$14.40 | +$2.00 |
| Q2 2025 | -$17.20 | -$0.40 |
| Q1 2025 | -$18.20 | -$1.20 |
| Q4 2024 | -$17.00 | +$1.60 |
| Q3 2024 | -$16.40 | +$3.20 |
| Q2 2024 | -$16.80 | +$2.60 |
| Q1 2024 | -$17.00 | +$2.40 |
| Q4 2023 | -$18.60 | +$0.60 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 188% for FEMY versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
FEMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $331.8K | -19% |
| Q1 2026 | $424.9K | +25% |
| Q4 2025 | $813.4K | +40% |
| Q3 2025 | $729.4K | +31% |
| Q2 2025 | $409.3K | +85% |
| Q1 2025 | $341.3K | +26% |
| Q4 2024 | $581.6K | +173% |
| Q3 2024 | $554.9K | +127% |
FEMY's revenue is growing: $331,827 last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1527% | -586 points |
| Q1 2026 | -994% | +606 points |
| Q4 2025 | -568% | +244 points |
| Q3 2025 | -501% | +422 points |
| Q2 2025 | -941% | +1083 points |
| Q1 2025 | -1600% | -323 points |
| Q4 2024 | -812% | +1276 points |
| Q3 2024 | -922% | +748 points |
FEMY's operating margin was −1527% last quarter, down 586 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over FEMY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over FEMY on profitability, with a higher operating margin.
FEMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.9M | +$501.9K |
| Q1 2026 | -$4.2M | +$639.2K |
| Q4 2025 | -$4.3M | +$856.3K |
| Q3 2025 | -$5.6M | +$300.9K |
| Q2 2025 | -$4.4M | +$62.1K |
| Q1 2025 | -$4.9M | -$229.1K |
| Q4 2024 | -$5.2M | -$2.1M |
| Q3 2024 | -$5.9M | -$3M |
FEMY has burned cash in almost every quarter: −$18M over the past year, against −$20M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over FEMY on cash generation, producing positive trailing cash flow while its opponent burns cash.
FEMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -548K shares |
| 1 year | +167% | +2.1M shares |
| 3 years | +468% | +2.8M shares |
| 5 years | +637% | +2.9M shares |
FEMY has 3M diluted shares, up 167% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | $161,761 |
| Q4 2024 | $30,093 |
| Q3 2024 | — |
| Q2 2024 | $6,593 |
| Q1 2024 | $24,067 |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over FEMY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
FEMY Net Leverage
FEMY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
FEMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 4.5 | Oversold |
FEMY's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
FEMY PE vs Healthcare Sector
FEMY has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
FEMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.73 | 19% below |
| 20 week MA | $2.55 | 45% below |
| 50 week MA | $7.09 | 80% below |
| 100 week MA | $13.3 | 89% below |
| 200 week MA | $17.3 | 92% below |
FEMY is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over FEMY on trend strength, trading above more of its moving averages.
FEMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $240.0 | $91.6 | -62% |
| 2022 | $91.6 | $18.6 | -80% |
| 2023 | $18.6 | $19.5 | +4.8% |
| 2024 | $19.5 | $22.6 | +16% |
| 2025 | $22.6 | $14.2 | -37% |
| 2026 YTD | $14.2 | $1.40 | -90% |
FEMY has finished lower in three of the last five years. It's down 90% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over FEMY on returns for 2026, with the stronger performance.